Bifosfonatos orais: considerações na área odontológica
DOI:
https://doi.org/10.35954/SM2015.34.2.4Palavras-chave:
Bifosfonatos; Osteonecrosis de los maxilares asociada a bifosfonatos; Reabsorción ÓseaResumo
Os bisfosfonatos, especialmente os administrados por via intravenosa, têm sido utilizados desde os anos 90 para o tratamento de doenças envolvendo tecido ósseo. Uma das complicações mais freqüentes de seu uso é a osteonecrose das mandíbulas. Os casos de osteonecrose do maxilar associada ao bisfosfonato estão geralmente relacionados a traumas menores, por exemplo, extrações dentárias e posterior exposição do osso ao ambiente oral, embora a etiopatogenia ainda não esteja totalmente determinada. O tratamento destas lesões é variado e adaptado ao estágio em que são encontradas, embora a prevenção seja primordial em cada caso.
Downloads
Referências
(1) Consolaro A. The use of bisphosphonates does not contraindicate orthodontic and other types of treatment! Dental Press J Orthod 2014; 19(4):18-26.
(2) Kumar V, Sinha R. Evolution and etiopathogenesis of bisphosphonates induced osteonecrosis of the jaw. N Am J Med Sci 2013; 5(4):260-5.
(3) Kalyan S, Wang J, Quabius E, Huck J, Wiltfang J, Baines J, et al. Systemic immunity shapes the oral microbiome and susceptibility to bisphosphonateassociated osteonecrosis of the jaw. J Transl Med 2015; 13: 212.
(4) Passeri LA, Bértolo MB, Abuabara A. Bisphosphonate -related osteonecrosis of the jaws. Rev Bras Reumatol 2011; 51(4):401-3, 407.
(5) Borgioli A, Viviani C, Duvina M, Brancato L, Spinelli G, Brandi ML, et al. Biphosphonates-related osteonecrosis of the jaw: Clinical and physiopathological considerations. Ther Clin Risk Manag 2009; 5(1):217-27.
(6) Khan A. Bisphosphonate-associated osteonecrosis of the jaw. Can Fam Physician 2008; 54(7):1019-21.
(7) Gómez-Moreno G, Arribas-Fernandez M, FernandezGuerrero M, Boquete-Castro A, Aguilar-Salvatierra A, Guardia J, et al. Bisphosphonate-associated osteonecrosis of the jaw 2 years after teeth extractions: a case report solved with non-invasive treatment. Eur Rev Med Pharmacol Sci 2014; 18 (9):1391-7.
(8) Kumar V; Kumar A. Nitrogen containing bisphosphonates associated osteonecrosis of the jaws: A review for past 10 year literature. Dent Res J (Isfahan). 2014; 11(2):147–153.
(9) Manzon L,Ettorre E, Viscogliosi G, Ippoliti S, Filiaci F, Ungari C, et al. Bisphosphonate therapy and osteonecrosis of the jaw complicated with a temporal abscess in an elderly woman with rheumatoid arthritis: a case report. Clin Interv Aging 2014; 9:1409-1413.
(10) Günaldi M, Usul Afsar C, Bozkurt Duman B, Oguz Kara I, Tatli U, and Sahin B. Effect of the cumulative dose of zoledronic acid on the pathogenesis of osteonecrosis of the jaws. Oncol Lett 2015; 10(1): 439-442.
(11) Zee Man Wat W. Current perspectives on bisphosphonate treatment in Paget's disease of bone. Ther Clin Risk Manag 2014; 10: 977-983.
(12) Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008; 83(9):1032-45.
(13) Oteri G, Bramanti E, Nigrone V, Cicciu M. Decayed, Missing, and Filled Teeth Index and Periodontal Health in Osteoporotic Patients Affected by BRONJ: An Observational Study. J Osteoporos 2013; 2013: 231289.
(14) Rasmusson L; Abtahi J. Bisphosphonate Associated Osteonecrosis of the Jaw: An Update on Pathophysiology, Risk Factors, and Treatment. Int J Dent 2014; 2014: 471035.
(15) Miniello TG, Araújo JP, Lopes RN, Alves FA. Osteonecrosis related to once-yearly zoledronic acid treatment in an osteoporotic patient after dental implant. Braz Dent J 2015; 26(1):86-8.
(16) Sigua-Rodriguez E, da Costa Ribeiro R, Ramos de Brito A, Alvarez-Pinzon N, de Albergaria-Barbosa J. Bisphosphonate-Related Osteonecrosis of the Jaw: A Review of the Literature. Int J Dent 2014; 2014: 192320.
(17) Scheper MA, Badros A, Chaisuparat R, Cullen KJ, Meiller TF. Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potencial mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol 2009; 144(5):667-76.
(18) Adler RA, Gill RS. Clinical utility of denosumab for treatment of bone loss in men and women. Clin Interv Aging 2011; 6:119-24.
(19) Kuiper JW, Forster C, Sun C, Peel S, Glogauer M. Zoledronate and pamidronate depress neutrophil functions and survival in mice. Br J Pharmacol 2012; 165(2):532-9.
(20) Roldan C; Paniagua L, Complications of New Medications. West J Emerg Med 2015; 16(1):154-156.
(21) Vescovi P, Meleti M, Merigo E, Manfredi M, Fornaini C, Guidotti R, et al. Case series of 589 tooth extractions in patients under bisphosphonates therapy. Proposal of a clinical protocol supported by Nd:YAG low-level laser therapy. Med Oral Patol Oral Cir Bucal 2013; 18(4):e680-5.
(22) Paulo S, Abrantes A, Laranjo M, Carvalho L, Serra A, Botelho M, et al. Bisphosphonate-Related Osteonecrosis of the Jaw: Specificities. Oncol Rev 2014; 8(2):254.
(23) Lorenzo S, Trapassi A, Corradino B, Cordova A. Histology of the Oral Mucosa in Patients with BRONJ at III Stage: A Microscopic Study Proves the Unsuitability of Local Mucosal Flaps. J Clin Med Res 2013; 5(1):22-5.
(24) Ro C, Cooper O. Bisphosphonate drug holiday: choosing appropriate candidates. Curr Osteoporos Rep 2013; 11(1):45-51.
(25) McGreevy C, Williams D. Safety of drugs used in the treatment of osteoporosis. Ther Adv Drug Saf 2011; 2(4):159-72.
(26) Otto S, Sotlar K, Ehrenfeld M, Pautke. Osteonecrosis of the jaw as a possible rare side effect of annual bisphosphonate administration for osteoporosis: A case report. J Med Case Rep 2011; 5:477.
(27) Mawardi H. Arole of oral bacteria in bisphosphonateinduced osteonecrosis of the jaw. J Dent Res 2011; 90(11):1339-45.
(28) Takaishi Y, Ikeo T, Nakajima M, Miki T, Fujita T. A pilot case-control study on the alveolar bone density measurement in risk assessment for bisphosphonaterelated osteonecrosis of the jaw. Osteoporos Int 2010; 21(5):815-25.
(29) Carey JJ, Palomo L. Bisphosphonates and osteonecrosis of the jaw: innocent association or significant risk? Cleve Clin J Med 2008; 75(12):871-9.
(30) Kang B, Cheong S, Chaichanasakul T, Bezouglaia O, Atti E, Dry SM, et al. Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice. J Bone Miner Res 2013; 28(7):1631-40.
(31) Albu S. Bisphosphonates and osteonecrosis of the maxilla. QJM 2014; 107(4):311.
(32) Kos M. Incidence and risk predictors for osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. Arch Med Sci 2015; 11(2):319–324.
(33) Flichy-Fernández A. Bisphosphonates and dental implants: current problems. Med Oral Patol Oral Cir Bucal 2009; 14(7):E355-60.
(34) Baillargeon J, Kuo YF, Lin YL, Wilkinson GS, Goodwin JS.. Osteonecrosis of the jaw in older osteoporosis patients treated with intravenous bisphosphonates. Ann Pharmacother 2011; 45(10):1199-1206.
(35) Hechmati G. Brett Hauber A, Arellano J, Mohamed, Qian Y, Gatta F, et al. Patient's preferences for bone metastases treatments in France, Germany and the United Kingdom. Support Care Cancer 2015; 23: 21-28.
(36) Mercer E, Norton T, Woo S, Treister N, Dodson TB, Solomon DH.. Ninety-one osteoporosis patients affected with bisphosphonate-related osteonecrosis of the jaw: a case series. Calcif Tissue Int 2013; 93(3):241-8.
(37) Hess LM, Jeter JM, Benham-Hutchins M, Alberts DS. Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med 2008; 121(6):475-483.
(38) Beninati , Pruneti R, Ficarra G. Bisphosphonaterelated osteonecrosis of the jaws (Bronj). Med Oral Patol Oral Cir Bucal 2013; 18(5):e752-8.
(39) Gallay L, Bodard AG, Chidiac C, Ferry T. Bilateral bisphosphonate-related osteonecrosis of the jaw with left chronic infection in an 82-year-old woman. BMJ Case Rep 2013; pii: bcr2013008558.
(40) Fedele S, Bedogni G, Scoletta M, Favia G, Colella G, Agrillo A, et al. Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed. Br J Oral Maxillofac Surg 2015; 53(1):13-7.
(41) Gupta S, Gupta H, Mandhyan D, Srivastava S. Bisphophonates related osteonecrosis of the jaw. Natl J Maxillofac Surg 2013; 4(2):151-8.
(42) Vidal-Real C, Pérez-Sayáns M, Suárez-Peñaranda J, Gándara-Rey J, García-García A. Osteonecrosis of the jaws in 194 patients who have undergone intravenous bisphosphonate therapy in Spain. Med Oral Patol Oral Cir Bucal 2015; 20(3): e267-e272.
(43) Jowett A, Abdullakutty A, Bailey M.Pathological fracture of the coronoid process secondary to medication-related osteonecrosis of the jaw (MRONJ). Int J Surg Case Rep 2015; 10:162–165.
(44) Huang Y, Ta Chang C, Hsin Muo C, Hao Tsai C, Yu Fu Shen, Zong Wu C. Impact of Bisphosphonate-related Osteonecrosis of the Jaw on Osteoporotic Patients after Dental Extraction: A Population-Based Cohort Study. PLoS ONE 10(4): e0120756.
(45) Matteos N, Caldwell P, Petcu EB, Ivanovski S, Reher P. Dental implant placement with bone augmentation in a patient who received intravenous bisphosphonate treatment for osteoporosis. J Can Dent Assoc 2013; 79:d2.
(46) Coskun Benlidayi I, Guzel R. Oral bisphosphonate related osteonecrosis of the jaw: a challenging adverse effect. ISRN Rheumatol 2013; 2013:215034.
(47) Tosi P, Zamagni E, Cangini D, Tacchetti P, Di Raimondo F, Catalano L et al. Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone. Blood 2006; 108(12):3951-2.
(48) Pelaz A, Junquera L, Gallego L, García-Consuegra L, García-Martínez L, Cutilli T, et al. Epidemiology, pharmacology and clinical characterization of bisphosphonate-related osteonecrosis of the jaw. A retrospective study of 70 cases. Acta Otorrinolaringol Esp 2015; 66(3):139-47.
(49) Campisi G, Fedele S, Fusco V, Pizzo G, Di Fede O, Bedogni A.. Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents. Future Oncol 2014; 10(2):257-75.
(50) Ikeda T, Kuraguchi J, Kogashiwa Y, Yokoi H, Satomi T, Kohno N. Successful treatment of isphosphonaterelated osteonecrosis of the jaw (BRONJ) patients with sitafloxacin: new strategies for the treatment of BRONJ. Bone 2015; 73:217-22.
(51) Pazianas M, Russell RG, Fogelman I. Osteonecrosis of the jaw: more heat than light. J Nucl Med. 2009; 50(1):6-7.
(52) Kyrgidis A, Andreadis C. Epidemiologic studies are needed to clarify whether dental modalities could be predictors of bisphosphonate osteonecrosis of the jaw in breast cancer patients. Oncologist 2009; 14(1):101-2.
(53) Ripamonti C, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G et al. Decreased occurrence of steonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 2009; 20(1):137-45.
(54) Kyrgidis A. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. J Clin Oncol 2008; 26(28):4634-8.
(55) Campisi G, Di Fede O, Musciotto A, Lo Casto A, Lo Muzio L, Fulfaro F, et al. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis. Ann Oncol 2007; 18 Suppl 6:168-72.
(56) Estefania R, Ponte Fernández R, Aguirre Urizar J. Bisphosphonates and oral pathology II. Osteonecrosis of the jaws: review of the literature before 2005. Med Oral Patol Oral Cir Bucal 2006; 11(6):e456-61.
(57) Mellado-Valero A. Implant treatment in patients with osteoporosis. Med Oral Patol Oral Cir Bucal 2010; 15(1):e52-7.
Publicado
Como Citar
Edição
Seção
Licença
Até 2024, usamos a licença Creative Commons Attribution/NonCommercial Attribution 4.0 International https://creativecommons.org/licenses/by-nc/4.0/deed.es. Que estabelece que: você é livre para compartilhar, copiar e redistribuir o material em qualquer meio ou formato, e para adaptar, remixar, transformar e desenvolver o material. De acordo com os seguintes termos:
Atribuição: você deve dar o devido crédito, fornecer um link para a licença e indicar se foram feitas alterações. Você pode fazer isso de qualquer forma razoável, mas não de uma forma que sugira que você ou seu uso é endossado pelo licenciante.
Não comercial: você não pode usar o material para fins comerciais.
A partir de 2025, os autores mantêm seus direitos autorais e cedem à revista o direito de primeira publicação de seu trabalho, que estará simultaneamente sujeito à licença https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es, que permite o compartilhamento, a cópia e a redistribuição do material em qualquer meio ou formato, desde que a publicação inicial nesta revista seja indicada. Adaptar, remixar, transformar e desenvolver o material. Se você remixar, transformar ou construir a partir do material, deverá distribuir sua contribuição sob a mesma licença do original e não poderá fazer uso do material para fins comerciais.
De acordo com os seguintes termos:
1. atribuição: você deve dar o devido crédito, fornecer um link para a licença e indicar se foram feitas alterações. Você pode fazer isso de qualquer maneira razoável, mas não de forma a sugerir que você ou seu uso seja endossado pelo licenciante.
2. não comercial: você não pode usar o material para fins comerciais.
3. ShareAlike: se você remixar, transformar ou desenvolver o material, deverá distribuir sua contribuição sob a mesma licença do original.
PlumX Metrics
